ARRIVENT BIOPHARMA INC (AVBP) Stock News

USA - NASDAQ:AVBP - US04272N1028 - Common Stock

19.59 USD

-0.4 (-2%)

Last: 10/21/2025, 8:00:00 PM

19.59 USD

0 (0%)

After Hours: 10/21/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AVBP Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

2 months ago - By: The Motley Fool

ArriVent Posts Wider Loss in Fiscal Q2

2 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

3 months ago - By: ArriVent BioPharma, Inc.

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

4 months ago - By: Benzinga - Mentions: CNC MOH BV MESO ...

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

4 months ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

a year ago - By: BusinessInsider

News Image

AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024

a year ago - By: InvestorPlace

AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024

4 months ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

4 months ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

4 months ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

5 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2025 Financial Results

7 months ago - By: Benzinga

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside

a year ago - By: BusinessInsider

News Image

AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024

a year ago - By: InvestorPlace

AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024

8 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Full Year 2024 Financial Results

9 months ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

a year ago - By: ArriVent BioPharma, Inc.

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

a year ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2024 Financial Results

a year ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2024 Financial Results

2 years ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints Kristine Peterson to its Board of Directors

2 years ago - By: ArriVent BioPharma, Inc.

ArriVent Appoints Kristine Peterson to its Board of Directors

2 years ago - By: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Full Year 2023 Financial Results